
Alegeți eticheta dumneavoastră
afișată direct pe flaconSemaglutide Oral
GLP-1 Oral
- Livrare din Germania
Comandă
- DHL cu urmărire
- Ambalare discretă
4.6 din 5 pe Trustpilot73 recenzii
Căutat și ca: Semaglutid Oral · Semaglutid Tabletten
Pe scurt
Semaglutide Oral în cifre
Valorile principale din lexiconul nostru.
Articolul complet din lexicon- Class
- GLP-1 agonistoral
- Half-life
- longdosed daily
- Use
- Oral, fastedin mg/day
- Sizes
- 2 sizes3mg/25tabs, 7mg/25tabs
What studies show
The source in the lexiconPIONEER 1: oral semaglutide as monotherapy in type 2 diabetes (randomized) (opens in a new tab)
Aroda et al., Diabetes Care, 2019
Pentru Semaglutide Oral nu există încă o analiză de laborator. Votați pentru elTestați-l singur, noi plătim jumătateToate analizele de laborator
Informații
Totul despre Semaglutide Oral
Informații detaliate în curând.
Is this the same compound as the injection?
Yes. Semaglutide is a GLP-1 analogue with 94 percent sequence match to the body's own GLP-1. The tablet also contains SNAC, which enables absorption in the stomach. Because only a small part arrives, the milligram figures are higher than with the injection.
Is oral semaglutide approved?
Yes. ChEMBL lists semaglutide as an approved compound with first approval in 2017, the tablet has its own US label. On ClinicalTrials.gov a search for oral semaglutide gives 204 trials (as of 26 October 2026). Everything here is the state of research, not a recommendation.
Why fasted and with little water?
According to the label only about 0.4 to 1 percent reaches the blood. In studies in healthy people absorption was higher with little water than with a large glass. The longer nothing was eaten after the tablet, the more arrived. Hence the strict intake rule in the entry.
What did PIONEER 1 show?
703 people with type 2 diabetes using only diet and exercise received one of three doses or placebo. After 26 weeks HbA1c was 0.6 to 1.1 percentage points lower than with placebo. Weight fell clearly only on the highest study dose, by 2.3 kg more than on placebo.
What about the heart?
PIONEER 6 with 3,183 people showed that cardiovascular risk does not rise (3.8 versus 4.8 percent). SOUL with 9,650 people with vascular or kidney disease found 12.0 instead of 13.8 percent major events over about four years, so 14 percent fewer.
Which side effects are typical?
Mainly gastrointestinal complaints. According to the label 20 percent had nausea on the highest study dose, 6 percent on placebo. In addition there were abdominal pain, diarrhoea, decreased appetite, vomiting and constipation. The label also names rare risks such as pancreatitis and gallbladder problems.
Produse asemănătoare
Produse similare
Semaglutide Oral